Sandbox: treatment
|
Multiple myeloma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Sandbox: treatment On the Web |
|
American Roentgen Ray Society Images of Sandbox: treatment |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Patients with smoldering (asymptomatic) multiple myeloma are managed by observation and undergoing follow up tests every 3 to 6 months. Whereas patients with active (symptomatic) multiple myeloma are treated with a combination of steroid therapy, immune modulator therapy and chemotherapy. The optimal therapy for active multiple myeloma depends on whether or not a patient is eligible for bone marrow transplantation. Patients who are candidates for bone marrow transplantation are treated by a combination of dexamethasone and lenalidomide/bortezomib in advance to their transplantation. Alkylating agents are not recommended among transplant eligible patients, as the toxicity of such agents makes the harvest of bone marrow stem cell difficult later in the course. Other pharmacological regimes used to treat active multiple myeloma patients eligible for bone marrow transplant may include either thalidomide, carfilzomib, cyclophosphamide, vincristine, or doxorubicin. In addition to the aforementioned agents, pharmacological regimes used for treatment of active multiple myeloma patients who are not eligible for bone marrow transplantation may include either melphalan or prednisone.
Medical Therapy
Smoldering multiple myeloma
- Patients with smoldering (asymptomatic) multiple myeloma are managed by observation and follow up tests every 3 to 6 months.
- Follow up studies of asymptomatic multiple myeloma patients include:
- Laboratory studies such as complete blood count, blood chemistry, 24 hour urine collection, electrophoresis, and quantitative immunoglobulin analysis
- Imaging studies such as skeletal survey, MRI, and PET scan
- Flow cytometry as needed
- Bone marrow aspiration and biopsy as needed
- Treatment should be differed until such patients develop symptoms.
Active multiple myeoloma
- The optimal therapy for active multiple myeloma depends on whether or not a patient is eligible for bone marrow transplantation.
- Deciding whether a patient is a candidate for bone marrow transplantation depends on a number of key factors that include:
- Age
- Presence of current associated diseases
- Patient's liver function
- Patient's kidney function
- Patient's cardiac function
Bone marrow transplant eligible patients
- Preferred pharmacological regimes for treating such patients include:
- Bortezomib/dexamethasone
- Bortezomib/dexamethasone/lenalidomide
- Dexamethasone/lenalidomide
- Bortezomib/dexamethasone/doxorubicin
- Bortezomib/dexamethasone/thalidomide
- Bortezomib/dexamethasone/cyclophosphamide
Bone marrow transplant ineligible patients
- Preferred pharmacological regimes for treating such patients include:
- Bortezomib/dexamethasone
- Low dose dexamethasone/lenalidomide
- Melphalan/prednisone/thalidomide
- Melphalan/prednisone/bortezomib
Supportive therapy
- Supportive therapy is recommended based on patient's symptoms and medication's side effects.
- Supportive therapy for active multiple myeloma includes:
- Bisphosphonates to prevent osteoporosis
- Erythropoietin to prevent anemia
- Vaccines to prevent recurrent infections
- Blood thinners to prevent blood clots
- Plasmapheresis to prevent hyperviscosity and renal failure